1. Home
  2. SLNG vs KPTI Comparison

SLNG vs KPTI Comparison

Compare SLNG & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stabilis Solutions Inc.

SLNG

Stabilis Solutions Inc.

N/A

Current Price

$4.55

Market Cap

92.0M

Sector

Utilities

ML Signal

N/A

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.40

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNG
KPTI
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.0M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SLNG
KPTI
Price
$4.55
$6.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$10.00
$22.17
AVG Volume (30 Days)
5.3K
177.9K
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$72,270,000.00
$142,530,000.00
Revenue This Year
$7.02
$3.82
Revenue Next Year
$7.68
$3.18
P/E Ratio
$89.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.29
$3.51
52 Week High
$8.28
$12.45

Technical Indicators

Market Signals
Indicator
SLNG
KPTI
Relative Strength Index (RSI) 39.08 55.12
Support Level $4.92 $5.99
Resistance Level $5.17 $7.48
Average True Range (ATR) 0.15 0.53
MACD -0.03 0.04
Stochastic Oscillator 6.06 51.38

Price Performance

Historical Comparison
SLNG
KPTI

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: